Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta-analysis
AIM:To compare neoadjuvant chemoradiotherapy and surgery with surgery alone for resectable esophageal carcinoma. METHODS:We used MEDLINE and EMBASE databases to identify eligible studies and manual searches were done to ensure no studies were missed.Trial validity assessment was performed and a tria...
Saved in:
Published in | World journal of gastroenterology : WJG Vol. 15; no. 47; pp. 5983 - 5991 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
21.12.2009
The WJG Press and Baishideng |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | AIM:To compare neoadjuvant chemoradiotherapy and surgery with surgery alone for resectable esophageal carcinoma. METHODS:We used MEDLINE and EMBASE databases to identify eligible studies and manual searches were done to ensure no studies were missed.Trial validity assessment was performed and a trial quality score was assigned. RESULTS:Eleven randomized controlled trials(RCTs) including 1308 patients were selected.Neoadjuvant chemoradiotherapy significantly improved the overall survival compared with surgery alone.Odds ratio(OR) [95%confidence interval(CI),P value],expressed as neoadjuvant chemoradiotherapy and surgery vs surgery alone,was 1.28(1.01-1.64,P=0.05)for 1-year survival,1.78(1.20-2.66,P=0.004)for 3-year survival,and 1.46(1.07-1.99,P=0.02)for 5-year survival.Postoperative mortality increased in patients treated by neoadjuvant chemoradiotherapy(OR: 1.68,95%CI:1.03-2.73,P=0.04),but incidence of postoperative complications was similar in two groups (OR:1.14,95%CI:0.88-1.49,P=0.32).Neoadjuvant chemoradiotherapy lowered the local-regional cancer recurrence(OR:0.64,95%CI:0.41-0.99,P=0.04), but incidence of distant cancer recurrence was similar (OR:0.94,95%CI:0.68-1.31,P=0.73).Histological subgroup analysis indicated that esophageal squamous cell carcinoma did not benefit from neoadjuvantchemoradiotherapy,OR(95%CI,P value)was 1.16(0.85-1.57,P=0.34)for 1-year survival,1.34 (0.98-1.82,P=0.07)for 3-year survival and 1.41 (0.98-2.02,P=0.06)for 5-year survival. CONCLUSION:Neoadjuvant chemoradiotherapy can raise the survival rate of patients with esophageal adenocarcinoma. |
---|---|
Bibliography: | Esophageal carcinoma Esophageal carcinoma; Neoadjuvant chemoradiotherapy; Randomized controlled trial; Metaanalysis 14-1219/R S896.3 S858.974 Randomized controlled trial Neoadjuvant chemoradiotherapy Metaanalysis ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 Author contributions: Jin HL and Shi RH designed the research; Jin HL, Zhu H and Ling TS performed the research; Jin HL, Zhang HJ and Shi RH wrote the paper. Correspondence to: Rui-Hua Shi, Professor, Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, China. ruihuashi@126.com Telephone: +86-25-83718836-6035 Fax: +86-25-83674636 |
ISSN: | 1007-9327 2219-2840 |
DOI: | 10.3748/wjg.15.5983 |